ArticleArchives of public health = Archives belges de sante publique2026
Cutaneous melanoma in Kazakhstan: epidemiological trends and economic burden on the healthcare system.
Article in Archives of public health = Archives belges de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous melanoma (CM) is a lethal skin malignancy with increasing global incidence and a growing economic burden. This study aimed to assess the epidemiological trends and healthcare expenditures associated with CM in Kazakhstan from 2019 to 2023.
methodsWe conducted a retrospective population-based study using data from the national oncology registry and the Healthcare Insurance Fund of Kazakhstan. Incident CM cases (ICD-10 C43-C43.9) diagnosed between 2019 and 2023 were analyzed. Demographic, clinical, and survival data were examined alongside healthcare expenditures for outpatient diagnostics, pharmaceutical treatment, and inpatient care. Multivariable Cox regression was used to assess factors associated with all-cause mortality.
resultsA total of 1,760 patients were included; 61% were female, and 46% were aged 51-70 years. Male patients had significantly higher rates of metastatic disease, nodal involvement, and mortality. From 2019 to 2023, CM prevalence increased from 24.7 to 62.7 per million, while mortality rose from 2.2 to 6.3 per million. Pharmaceutical spending surged nearly tenfold, from USD 4.1 million to USD 38.0 million, while outpatient diagnostic and inpatient treatment costs more than doubled. Whole-body PET scans and BRAF testing accounted for a growing share of outpatient costs. Significant mortality predictors included male sex (HR = 1.59), age ≥ 71 years (HR = 1.87), ECOG score, metastases, and lymph node involvement (p < 0.05).
conclusionCM imposes an increasing clinical and financial burden on Kazakhstan's healthcare system. Rising prevalence and escalating treatment costs highlight the need for early detection, improved disease management, and cost-effective interventions to reduce the long-term impact of melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.